210 related articles for article (PubMed ID: 29665050)
21. Selective HDAC6 inhibition prevents TNF-α-induced lung endothelial cell barrier disruption and endotoxin-induced pulmonary edema.
Yu J; Ma Z; Shetty S; Ma M; Fu J
Am J Physiol Lung Cell Mol Physiol; 2016 Jul; 311(1):L39-47. PubMed ID: 27190059
[TBL] [Abstract][Full Text] [Related]
22. Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells.
Rouhi A; Miller C; Grasedieck S; Reinhart S; Stolze B; Döhner H; Kuchenbauer F; Bullinger L; Fröhling S; Scholl C
Oncotarget; 2017 Jan; 8(5):7678-7690. PubMed ID: 28032595
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of HDAC6 by tubastatin A disrupts mouse oocyte meiosis via regulating histone modifications and mRNA expression.
Sui L; Huang R; Yu H; Zhang S; Li Z
J Cell Physiol; 2020 Oct; 235(10):7030-7042. PubMed ID: 32017059
[TBL] [Abstract][Full Text] [Related]
24. Overexpressed HDAC8 in cervical cancer cells shows functional redundancy of tubulin deacetylation with HDAC6.
Vanaja GR; Ramulu HG; Kalle AM
Cell Commun Signal; 2018 May; 16(1):20. PubMed ID: 29716651
[TBL] [Abstract][Full Text] [Related]
25. BIIB021, a novel Hsp90 inhibitor, sensitizes esophageal squamous cell carcinoma to radiation.
Wang XT; Bao CH; Jia YB; Wang N; Ma W; Liu F; Wang C; Wang JB; Song QX; Cheng YF
Biochem Biophys Res Commun; 2014 Oct; 452(4):945-50. PubMed ID: 25223594
[TBL] [Abstract][Full Text] [Related]
26. A novel Hsp90 inhibitor AT13387 induces senescence in EBV-positive nasopharyngeal carcinoma cells and suppresses tumor formation.
Chan KC; Ting CM; Chan PS; Lo MC; Lo KW; Curry JE; Smyth T; Lee AW; Ng WT; Tsao GS; Wong RN; Lung ML; Mak NK
Mol Cancer; 2013 Oct; 12(1):128. PubMed ID: 24156782
[TBL] [Abstract][Full Text] [Related]
27. Tubacin, an HDAC6 Selective Inhibitor, Reduces the Replication of the Japanese Encephalitis Virus via the Decrease of Viral RNA Synthesis.
Lu CY; Chang YC; Hua CH; Chuang C; Huang SH; Kung SH; Hour MJ; Lin CW
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28468311
[TBL] [Abstract][Full Text] [Related]
28. Hsp90 inhibition by PU-H71 induces apoptosis through endoplasmic reticulum stress and mitochondrial pathway in cancer cells and overcomes the resistance conferred by Bcl-2.
Gallerne C; Prola A; Lemaire C
Biochim Biophys Acta; 2013 Jun; 1833(6):1356-66. PubMed ID: 23485394
[TBL] [Abstract][Full Text] [Related]
29. Histone deacetylase 6 and heat shock protein 90 control the functions of Foxp3(+) T-regulatory cells.
de Zoeten EF; Wang L; Butler K; Beier UH; Akimova T; Sai H; Bradner JE; Mazitschek R; Kozikowski AP; Matthias P; Hancock WW
Mol Cell Biol; 2011 May; 31(10):2066-78. PubMed ID: 21444725
[TBL] [Abstract][Full Text] [Related]
30. CG0006, a novel histone deacetylase inhibitor, induces breast cancer cell death via histone-acetylation and chaperone-disrupting pathways independent of ER status.
Kim HM; Kim CS; Lee JH; Jang SJ; Hwang JJ; Ro S; Hyun YL; Choi J
Breast Cancer Res Treat; 2011 Nov; 130(2):365-75. PubMed ID: 21184271
[TBL] [Abstract][Full Text] [Related]
31. Pharmacological inhibition of HDAC6 overcomes cisplatin chemoresistance by targeting cancer stem cells in oral squamous cell carcinoma.
Tavares MO; Milan TM; Bighetti-Trevisan RL; Leopoldino AM; de Almeida LO
J Oral Pathol Med; 2022 Jul; 51(6):529-537. PubMed ID: 35678235
[TBL] [Abstract][Full Text] [Related]
32. Carbamazepine promotes Her-2 protein degradation in breast cancer cells by modulating HDAC6 activity and acetylation of Hsp90.
Meng Q; Chen X; Sun L; Zhao C; Sui G; Cai L
Mol Cell Biochem; 2011 Feb; 348(1-2):165-71. PubMed ID: 21082217
[TBL] [Abstract][Full Text] [Related]
33. The HDAC/HSP90 Inhibitor G570 Attenuated Blue Light-Induced Cell Migration in RPE Cells and Neovascularization in Mice through Decreased VEGF Production.
Hsu TJ; Nepali K; Tsai CH; Imtiyaz Z; Lin FL; Hsiao G; Lai MJ; Cheng YW
Molecules; 2021 Jul; 26(14):. PubMed ID: 34299636
[TBL] [Abstract][Full Text] [Related]
34. Limited efficacy of specific HDAC6 inhibition in urothelial cancer cells.
Rosik L; Niegisch G; Fischer U; Jung M; Schulz WA; Hoffmann MJ
Cancer Biol Ther; 2014 Jun; 15(6):742-57. PubMed ID: 24618845
[TBL] [Abstract][Full Text] [Related]
35. HDAC6 inhibition results in tau acetylation and modulates tau phosphorylation and degradation in oligodendrocytes.
Noack M; Leyk J; Richter-Landsberg C
Glia; 2014 Apr; 62(4):535-47. PubMed ID: 24464872
[TBL] [Abstract][Full Text] [Related]
36. Regulation of the dynamics of hsp90 action on the glucocorticoid receptor by acetylation/deacetylation of the chaperone.
Murphy PJ; Morishima Y; Kovacs JJ; Yao TP; Pratt WB
J Biol Chem; 2005 Oct; 280(40):33792-9. PubMed ID: 16087666
[TBL] [Abstract][Full Text] [Related]
37. HDAC6 inhibition disrupts maturational progression and meiotic apparatus assembly in mouse oocytes.
Ling L; Hu F; Ying X; Ge J; Wang Q
Cell Cycle; 2018; 17(5):550-556. PubMed ID: 28598228
[TBL] [Abstract][Full Text] [Related]
38. Structure-based design generated novel hydroxamic acid based preferential HDAC6 lead inhibitor with on-target cytotoxic activity against primary choroid plexus carcinoma.
Kassab SE; Mowafy S; Alserw AM; Seliem JA; El-Naggar SM; Omar NN; Awad MM
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1062-1077. PubMed ID: 31072216
[TBL] [Abstract][Full Text] [Related]
39. Uropathogenic Escherichia coli invades host cells via an HDAC6-modulated microtubule-dependent pathway.
Dhakal BK; Mulvey MA
J Biol Chem; 2009 Jan; 284(1):446-454. PubMed ID: 18996840
[TBL] [Abstract][Full Text] [Related]
40. A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth.
Kaliszczak M; Trousil S; Åberg O; Perumal M; Nguyen QD; Aboagye EO
Br J Cancer; 2013 Feb; 108(2):342-50. PubMed ID: 23322205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]